Cogent Biosciences Inc Sustainability Reports
A clinical-stage biotechnology company developing precision small molecule therapeutics, primarily focusing on bezuclastinib (CGT9486) for genetically defined diseases like Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST).
Sector: Professional & technical services
Country: United States
Exchange: Nasdaq
3 reports from 2020 to 2023
Company Profile
A clinical-stage biotechnology company developing precision small molecule therapeutics, primarily focusing on bezuclastinib (CGT9486) for genetically defined diseases like Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST).
Reports
3 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
